Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

InterveXion reports phase II data on IXT-m200 in methamphetamine use disorder

April 20, 2021

FDA approves new expanded indication for Anavip

April 7, 2021

First subjects dosed in study comparing nasal nalmefene with nasal naloxone

April 6, 2021

Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms

April 1, 2021

Brain cell alcohol metabolism affects behavior, addiction

March 25, 2021

DemeRx receives approval for phase I/II study of ibogaine in the U.K.

March 11, 2021

FDA gives clearance to initiate clinical development of KP-879

Jan. 28, 2021

Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment

Jan. 26, 2021

New adenosine A2A receptor antagonists presented by AMMS

Jan. 13, 2021

Braeburn receives complete response letter for Brixadi in the U.S.

Dec. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.